Search research articles
Contact Us
Filters
Showing results (41-50 of 106) with videos related to
Page
of 11
Sort By:
Nature Biotechnology
|
March 10, 2015
Shire bags NPS, including newly approved biologic for hypoparathyroidism
Mark Ratner
Nature Biotechnology
|
January 11, 2014
Genentech's glyco-engineered antibody to succeed Rituxan
Mark Ratner
Nature Biotechnology
|
April 9, 2009
Pharma swept up in biogenerics gold rush
Mark Ratner
Nature Biotechnology
|
January 9, 2016
Off-the-shelf CAR-T therapy induces remission in child with ALL
Mark Ratner
Nature Biotechnology
|
January 10, 2015
IBM's Watson Group signs up genomics partners
Mark Ratner
Nature Biotechnology
|
August 9, 2017
First multi-gene NGS diagnostic kit approved
Mark Ratner
Nature Biotechnology
|
November 8, 2014
Landmark approvals in idiopathic pulmonary fibrosis
Mark Ratner
Nature Biotechnology
|
July 9, 2015
Alexion pays big for Synageva's rare disease drug candidate
Mark Ratner
Nature Biotechnology
|
December 9, 2010
Crossing the line
Mark Ratner
Nature Biotechnology
|
July 9, 2014
Odds still favor Novartis heart failure drug Serelaxin
Mark Ratner
Page
of 11
Search research articles
Search
Showing results (41-50 of 106) with videos related to
Sort By:
Page
of 11
Nature Biotechnology
|
March 10, 2015
Shire bags NPS, including newly approved biologic for hypoparathyroidism
Mark Ratner
Nature Biotechnology
|
January 11, 2014
Genentech's glyco-engineered antibody to succeed Rituxan
Mark Ratner
Nature Biotechnology
|
April 9, 2009
Pharma swept up in biogenerics gold rush
Mark Ratner
Nature Biotechnology
|
January 9, 2016
Off-the-shelf CAR-T therapy induces remission in child with ALL
Mark Ratner
Nature Biotechnology
|
January 10, 2015
IBM's Watson Group signs up genomics partners
Mark Ratner
Nature Biotechnology
|
August 9, 2017
First multi-gene NGS diagnostic kit approved
Mark Ratner
Nature Biotechnology
|
November 8, 2014
Landmark approvals in idiopathic pulmonary fibrosis
Mark Ratner
Nature Biotechnology
|
July 9, 2015
Alexion pays big for Synageva's rare disease drug candidate
Mark Ratner
Nature Biotechnology
|
December 9, 2010
Crossing the line
Mark Ratner
Nature Biotechnology
|
July 9, 2014
Odds still favor Novartis heart failure drug Serelaxin
Mark Ratner
Page
of 11